Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
By: Ross Blau
Life Sciences IP Review
Axinn associate Ross Blau co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."
Click here to access the publication. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust
Informa CompLaw Advanced EU Conference 2026
Sponsorship
Antitrust
Wild Tomorrow 2026 Annual Gala
Sponsorship
Antitrust
NAPABA Annual Convention 2026
Sponsorship
Antitrust
Law.com General Counsel Conference East 2026
Sponsorship
Antitrust
Economist Enterprise's 1st Annual Antitrust Summit US
Sponsorship
Antitrust
